Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma
Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well busulfan, melphalan, and bortezomib before first-line
stem cell transplant works in treating patients with multiple myeloma. Giving chemotherapy
before a peripheral blood stem cell transplant may stop the growth of cancer cells by
stopping them from dividing or killing them. After treatment, stem cells are collected from
the patient's blood and stored. The stem cells are then returned to the patient to replace
the blood-forming cells that were destroyed by the chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Albert Einstein College of Medicine Albert Einstein College of Medicine of Yeshiva University